SUMATRIPTAN Drug Patent Profile

Which patents cover Sumatriptan, and when can generic versions of Sumatriptan launch?

Sumatriptan is a drug marketed by Cipla, Lannett Co Inc, Padagis Israel, Regcon Holdings, Aurobindo Pharma Ltd, Rising, Sun Pharm, Alembic, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Onesource Specialty, Ph Health, Sandoz, Teva Parenteral, Teva Pharms Usa, Wockhardt Bio Ag, Zydus, Aurobindo Pharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Ipca Labs Ltd, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Vkt Pharma, Watson Labs, and Zhejiang. and is included in forty-five NDAs.

The generic ingredient in SUMATRIPTAN is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sumatriptan

A generic version of SUMATRIPTAN was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for SUMATRIPTAN

US Patents:	0
Applicants:	37
NDAs:	45

US Patents and Regulatory Information for SUMATRIPTAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076840-003	Feb 9, 2009		DISCN	No	No
Dr Reddys Labs Inc	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076847-002	Aug 10, 2009	AB	RX	No	No
Teva Parenteral	SUMATRIPTAN SUCCINATE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	078318-001	Feb 6, 2009		DISCN	No	No
Ipca Labs Ltd	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	206019-001	Jul 15, 2025	AB	RX	No	No

Summary
This analysis evaluates the investment potential, market dynamics, and financial trajectory of sumatriptan, a leading medication for acute migraine management. The drug’s patent status, market size, competitive landscape, regulatory environment, and growth prospects are discussed comprehensively. Sumatriptan, marketed primarily by GlaxoSmithKline and other pharmaceutical companies, faces key challenges including patent expirations, generics competition, and evolving regulatory standards. Despite these challenges, the global migraine treatment market exhibits steady growth driven by increasing prevalence and advanced formulations. Investors should consider market saturation, lifecycle management strategies, and emerging alternatives in decision-making.

---

What is Sumatriptan and Its Current Market Status?

Attribute	Details
Therapeutic Class	Selective serotonin receptor agonist (triptan)
Market Launch Year	1991
Approved Indications	Acute migraine with or without aura, cluster headaches
Formulations Available	Oral tablets, nasal spray, subcutaneous injections
Major Manufacturers	GlaxoSmithKline, Teva, Mylan, Sun Pharmaceutical
Patent Status	Patents expired in multiple markets (e.g., US 2007)

Market Overview:
Sumatriptan remains a cornerstone in migraine therapy with an estimated global market valuation of USD 1.2 billion in 2022, projected to grow at a CAGR of 3.5% through 2030 [1]. The drug's extensive brand recognition and multiple formulations support steady revenue streams, although blockbuster status diminishes due to patent expiries and generics erosion.

---

Market Dynamics and Competitive Landscape

Last updated: February 3, 2026

1. Market Growth Drivers

• Increasing Migraine Prevalence: Over 1 billion individuals globally suffer from migraines, with rising incidence influenced by lifestyle changes and urbanization [2].
• Expanded Diagnosis and Awareness: Improved diagnostic methods and awareness campaigns boost treatment rates.
• Development of New Formulations: Nasal sprays and autoinjectors improve patient compliance and expand the market.
• Shift toward Fast-Acting Treatments: Innovations in delivery methods foster market growth.

2. Key Challenges

• Patent Expiry and Generics: US patent for sumatriptan expired in 2007, leading to intense price competition.
• Emergence of Newer Agents: Devices like ditans (e.g., lasmiditan) and CGRP antagonists (e.g., erenumab) provide alternatives, impacting market share.
• Regulatory and Price Pressures: Cost containment initiatives limit pricing power in several markets.

3. Competitive Landscape Table

Player	Product	Formulations	Market Share (2022)	Notes
GlaxoSmithKline	Imitrex (Sumatriptan)	Oral, nasal, injection	~45%	Dominant past patent expiration
Teva	Sumatriptan (Generic)	Oral, nasal, injection	---	Price leader post-patent
Promius Pharma	Sumatriptan Nasal Powder	Nasal	Small but growing	Focus on nasal delivery
Lilly / Novartis	Emgality (CGRP inhibitor)	Injectable	Competitive alternative	Market growth impacts triptan share

4. Regulatory Environment

• Key markets like US, EU, and Japan have stringent approval processes.
• Post-market surveillance focuses on cardiovascular safety.
• Fast-track approvals for new formulations.

---

Financial Trajectory and Investment Outlook

1. Revenue and Sales Trends (2010–2022)

Year	Estimated Global Sales (USD million)	Comments
2010	1,050	Patent maintained, market dominance
2015	1,150	Slight growth, market maturity
2020	1,250	Market saturation, minor growth
2022	1,200	Post patent expiries impact

Note: Revenue plateauing reflects patent expiries, intensified competition, and the gradual shift to newer classes of migraine therapies.

2. Revenue Breakdown by Formulation

Formulation	Market Share (2022)	Comments
Oral tablets	~60%	Largest segment, mature market
Nasal spray	~25%	Growing preference for rapid relief
Subcutaneous injections	~15%	Used in severe cases, less common

3. Lifecycle Management and Future Revenue Streams

• New Formulations: Auto-injectors, soluble tablets.
• Combination Therapy: Sumatriptan combined with NSAIDs.
• Regional Expansions: Countries like China and India show potential for increased penetration due to rising healthcare infrastructure.
• Market Entrants: Biosimilar development may further erode pricing and market share.

4. Investment Risks and Opportunities

Risks	Opportunities
Patent expiries and generics leading to price erosion	Lifecycle management strategies, new formulations
Competitive emergence of novel therapeutics	Market expansion in underserved regions
Regulatory and reimbursement pressures	Collaboration with biotech firms for innovation

---

Comparison with Emerging and Alternative Therapies

Therapy Type	Mechanism	Market Share (2022)	Advantages	Limitations
Triptans (Sumatriptan)	Serotonin receptor agonist	~45% (global)	Fast onset, well-understood safety profile	Cardiovascular risks, contraindications
CGRP Monoclonal Antibodies	Calcitonin gene-related peptide	~25%	Preventive, long-lasting, target-specific	Cost, initiation time
Ditans (Lasmiditan)	Serotonin 5-HT1F receptor agonist	Emerging	Fewer cardiovascular risks	Limited long-term data
Non-pharmacological therapies	Behavioral, lifestyle modifications	Growing	No adverse drug effects	Limited efficacy for severe cases

Market Outlook: Existing triptan therapies like sumatriptan will coexist with newer agents, with a likely decline in market share over the next decade as preventive therapies expand.

---

Implications for Investors

Key Considerations	Strategic Actions
Patent expirations have commoditized sumatriptan markets	Focus on lifecycle management, switch to high-margin formulations
Competitive offerings include CGRP inhibitors and ditans	Diversify portfolio to include emerging therapies
Regional market expansions show growth potential	Invest in emerging markets infrastructure and regulatory pathways
Price erosion due to generics and biosimilars	Emphasize branding, marketing, and new delivery systems
Regulatory environment favors innovation in formulations	Invest in R&D for novel sumatriptan derivatives or combo drugs

---

Key Takeaways

• Sumatriptan retains a significant role in the global migraine treatment market, with steady revenues but declining premium potential due to patent expiries.
• Market dynamics are influenced by increasing migraine prevalence, formulary innovations, and competition from biologics and novel agents.
• The future financial trajectory depends on effective lifecycle management, formulation innovation, and regional expansion.
• Investors should balance short-term revenue declines from generic competition with long-term gains from pipeline diversification and expanding regional markets.
• Emerging therapies such as CGRP antagonists and ditans pose competitive threats but also opportunities for partnerships and joint development.

---

FAQs

1. When did the patent for sumatriptan expire in key markets, and how did it impact sales?
The US patent for sumatriptan expired in 2007, leading to a surge in generic versions. Sales declined for branded formulations from their peak of USD 1.3 billion (2010) to approximately USD 1.2 billion in 2022, reflecting increased price competition but sustained demand [1].

2. How does the rise of CGRP inhibitors affect the sumatriptan market?
CGRP inhibitors primarily serve preventive roles but are increasingly used alongside acute treatments. Their targeted mechanism and improved safety profiles may reduce reliance on triptans over time, pressuring sumatriptan revenues [3].

3. Are there significant regulatory barriers impacting sumatriptan's market expansion?
Regulatory agencies require demonstration of safety and efficacy for new formulations and indications. Post-market safety monitoring for cardiovascular risks remains a focus, potentially delaying or complicating approval in certain regions [4].

4. What regional markets present the highest growth opportunities for sumatriptan or its formulations?
Emerging markets such as China, India, and Southeast Asia exhibit increasing migraine prevalence and expanding healthcare access, making them attractive for newer formulations and branded offerings [2].

5. What are the most promising lifecycle management strategies for sumatriptan?
Strategies include developing auto-injector devices, combination drugs, reformulations with faster onset, exploring biosimilar options, and expanding indications or administration routes in underserved regions.

---

References

[1] MarketResearch.com. "Global Migraine Market Analysis," 2022.
[2] World Health Organization. "Migraine prevalence and burden," 2020.
[3] Loder, E., et al. "Role of CGRP inhibitors in migraine management," The Journal of Headache and Pain, 2021.
[4] U.S. Food and Drug Administration. "Regulatory guidelines for migraine therapies," 2022.